203 related articles for article (PubMed ID: 30906662)
1. Correlation between patients' age and cancer immunotherapy efficacy.
Wu Q; Wang Q; Tang X; Xu R; Zhang L; Chen X; Xue Q; Wang Z; Shi R; Wang F; Ju F; Zhang B; Zhou YL
Oncoimmunology; 2019; 8(4):e1568810. PubMed ID: 30906662
[No Abstract] [Full Text] [Related]
2. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.
Nishijima TF; Muss HB; Shachar SS; Moschos SJ
Cancer Treat Rev; 2016 Apr; 45():30-7. PubMed ID: 26946217
[TBL] [Abstract][Full Text] [Related]
3. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
[TBL] [Abstract][Full Text] [Related]
4. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yan X; Tian X; Wu Z; Han W
Front Oncol; 2020; 10():1671. PubMed ID: 33072551
[No Abstract] [Full Text] [Related]
5. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.
Kim CM; Lee JB; Shin SJ; Ahn JB; Lee M; Kim HS
ESMO Open; 2022 Oct; 7(5):100577. PubMed ID: 36156450
[TBL] [Abstract][Full Text] [Related]
7. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
8. The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis.
Li P; Yang X; Feng Y; Wu L; Ma W; Ding G; Wei Y; Sun L
Onco Targets Ther; 2018; 11():7521-7527. PubMed ID: 30464500
[TBL] [Abstract][Full Text] [Related]
9. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
An Y; Wu Z; Wang N; Yang Z; Li Y; Xu B; Sun M
J Transl Med; 2020 Jun; 18(1):235. PubMed ID: 32532255
[TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review.
Kim BJ; Kim JH; Kim HS
Oncotarget; 2017 Aug; 8(31):51779-51785. PubMed ID: 28881686
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis.
Li J; Gu J
Future Oncol; 2019 Nov; 15(31):3633-3646. PubMed ID: 31650854
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Wang S; Hao J; Wang H; Fang Y; Tan L
Oncoimmunology; 2018; 7(8):e1457600. PubMed ID: 30221052
[TBL] [Abstract][Full Text] [Related]
15. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
16. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
[TBL] [Abstract][Full Text] [Related]
17. Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Ninomiya K; Oze I; Kato Y; Kubo T; Ichihara E; Rai K; Ohashi K; Kozuki T; Tabata M; Maeda Y; Kiura K; Hotta K
Acta Oncol; 2020 Mar; 59(3):249-256. PubMed ID: 31782328
[No Abstract] [Full Text] [Related]
18. Antibiotic exposure windows and the efficacy of immune checkpoint blockers in patients with cancer: a meta-analysis.
Huang L; Chen X; Zhou L; Xu Q; Xie J; Zhan P; Lv T; Song Y
Ann Palliat Med; 2021 Mar; 10(3):2709-2722. PubMed ID: 33549013
[TBL] [Abstract][Full Text] [Related]
19. Smoking history and the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis.
Chen DL; Li QY; Tan QY
J Thorac Dis; 2021 Jan; 13(1):220-231. PubMed ID: 33569202
[TBL] [Abstract][Full Text] [Related]
20. Effect of region on the Outcome of Patients Receiving PD-1/PD-L1 Inhibitors for Advanced Cancer.
Wang Z; Zhang B; Zhang C; Ren S; Wang W; Wang Y; Jiang T; Wei H; Li Y; Wu Q; Chen J
Int Immunopharmacol; 2019 Sep; 74():105709. PubMed ID: 31276976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
